多柔比星、达卡巴嗪与纳武利尤单抗联合作为晚期平滑肌肉瘤一线治疗的Ib期研究:西班牙肉瘤组(GEIS)研究
这项Ib期研究评估多柔比星、达卡巴嗪联合纳武利尤单抗一线治疗晚期平滑肌肉瘤,采用经典3+3设计确定II期推荐剂量。24例患者入组,23例可评估疗效,毒性以4级中性粒细胞减少(16.7%)和血小板减少(8.3%)最常见,无5级毒性。中心审查的客观缓解率为部分缓解56.5%、疾病稳定39.1%、进展4.4%,6个月无进展生存率80%(95%CI 63至98)。
要点
- 该联合方案可行且耐受性良好,最常见4级毒性为中性粒细胞减少(16.7%)和血小板减少(8.3%),无5级毒性。
- 中心审查的客观缓解率为部分缓解56.5%、疾病稳定39.1%、进展4.4%。
- 6个月无进展生存率为80%(95%CI 63至98),血中HMGB1动态升高与更长无进展生存显著相关。
核心结论
- 多柔比星、达卡巴嗪与纳武利尤单抗联合方案可行且耐受性良好,临床活性令人鼓舞,HMGB1的预后影响支持免疫原性细胞死亡激活的相关性。
- 作者指出针对该概念在平滑肌肉瘤中的进一步临床研究已在进行中。
研究设计与样本
- Ib期试验,采用经典3+3剂量递增设计确定II期推荐剂量(RP2D)。
- 入组晚期平滑肌肉瘤且未接受过蒽环类药物的患者。
- 初始剂量水平为多柔比星75 mg/m2第1天一次、每3周一次,随后达卡巴嗪400 mg/m2第1天和第2天各一次、每3周一次,加纳武利尤单抗360 mg第2天一次、每3周一次,共6个疗程,之后纳武利尤单抗治疗1年。
- (-1)剂量水平方案相同但纳武利尤单抗为240 mg。
- 2002年1月至2023年7月共入组24例患者,23例可评估疗效,排除1例因剂量不依从。
主要发现
- 毒性轻微,最常见的4级毒性为中性粒细胞减少(16.7%)和血小板减少(8.3%),无5级毒性发生。
- 中心审查的客观缓解率为:部分缓解56.5%、疾病稳定39.1%、进展4.4%。
- 6个月无进展生存(PFS)率为80%(95%CI 63至98)。
- 血中HMGB1的动态升高与更长的PFS显著相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Doxorubicin, alongside a select group of cytotoxic agents, is capable of inducing an adaptive immune response via a well-established peculiar type of tumor cell death called immunogenic cell death (ICD). We hypothesize that combining doxorubicin and dacarbazine with nivolumab may enhance therapeutic efficacy by exerting synergy in the ICD circuit. We hereby present a phase Ib trial with this combination. PATIENTS AND METHODS: Patients with advanced leiomyosarcoma and anthracycline-naïve were eligible. The initial dose level consisted of doxorubicin 75 mg/m2 once on day 1, once every three weeks, followed by dacarbazine 400 mg/m2 once on days 1 and 2, once every three weeks, plus nivolumab 360 mg once on day 2, once every 3 weeks, for six courses and then 1 year of nivolumab. A (-1) dose level was the same regimen but with nivolumab 240 mg. A classic 3 + 3 phase-I design was used to determine the recommended phase-II dose (RP2D). Secondary end points included overall response rate, safety profile, survival, and translational research. RESULTS: From January 2002 to July 2023, 24 patients were enrolled and 23 were evaluable for efficacy, excluding one patient because of noncompliant dose. All patients were treated with the initial dose level, then the RP2D. Toxicity was mild, with the most frequent being grade 4 toxicity neutropenia (16.7%) and thrombocytopenia (8.3%), while no grade 5 toxicity occurred. The centrally reviewed objective response rate was as follows: partial response 56.5%, stable disease 39.1%, and progression 4.4%. The 6-month progression-free survival (PFS) rate was 80% (95% CI, 63 to 98). Dynamic increases of HMGB1 in blood significantly correlated with longer PFS. CONCLUSION: This scheme of doxorubicin, dacarbazine, and nivolumab is feasible and well tolerated. Clinical activity is encouraging and the prognostic impact of HMGB1 supports the relevance of ICD activation. Further clinical research is already underway with this concept in leiomyosarcoma.
引用
- Martin-Broto J, Diaz-Beveridge R, Moura D, et al. Phase Ib Study for the Combination of Doxorubicin, Dacarbazine, and Nivolumab as the Upfront Treatment in Patients With Advanced Leiomyosarcoma: A Study by the Spanish Sarcoma Group (GEIS). J Clin Oncol. 2024. PMID: 39356980. doi:10.1200/JCO.24.00358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。